Author:
Danyeli Lena V.,Götting Florian N.,Sen Zümrüt Duygu,Li Meng,Walter Martin
Publisher
Springer International Publishing
Reference285 articles.
1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Stimul Res Treat Depress Electroconvulsive Ther Transcranial Magn Stimul Deep Brain Stimul. 2010;67(2):139–45.
2. Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, et al. Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2017;42(6):1210–9.
3. Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J Anal Toxicol. 2005;29(5):376–82.
4. Adams JD, Castagnoli N, Trevor AJ. Quantitative analysis of ketamine enantiomers. Proc West Pharmacol Soc. 1978;21:471–2.
5. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology. 2013;230(2):291–8.